Integrated Tools for Quantitative Whole-Body Tumor Perfusion Imaging

Project: Research projectResearch Project

Description

AbstractCurrent imaging-based techniques for quantitative assessment of tissue perfusion require complex dataacquisition and analysis strategies; typically require ancillary blood sampling for measurement of inputfunctions; are limited to a single organ or tissue region; and because of their complexity are not well suited as abiomarker for cancer clinical trials or patient management. We hypothesize that the 62Cu-labeled copper(II)bis(thiosemicarbazone) complexes, Cu-ETS and Cu-ETSM, will provide a platform for quantitative estimationof tissue perfusion throughout whole-body images utilizing methods that are rapid, and computationallysuitable, for widespread routine clinical application. The objective of this academic-industrial partnershipproposal is to translate very promising initial results into a fully validated whole-body quantitative perfusionimaging method for use as a biomarker in cancer clinical trials and precision medicine treatment strategies.This partnership will bring together three key teams of investigators to: i. fully develop and validate the 62Cuquantitative perfusion method (Indiana University); ii. refine the 62Zn/62Cu generator production technology toenable wide-spread generator distribution (Zevacor Molecular, Inc.); and iii. to establish a software processingplatform to facilitate harmonization of data analysis across diverse imaging centers (MIM Software, Inc. andIndiana University). The significance of this research includes the abilities to: (1) quantitatively assess thevascular effects of therapeutic agents on tumors throughout the body; (2) assess non-target side-effects intissues throughout the whole body; (3) establish disease phenotype in both primary and metastatic lesions(and patient prognosis) by combining whole-body metabolism and perfusion measurements; (4) monitor thetransition of tumors from a drug-responsive to a drug-resistant phenotype (and/or assess durability ofresponse); (5) assess the extent of comorbidities that manifest with perfusion abnormalities (e.g.,cardiovascular, cerebrovascular, renal, and peripheral vascular diseases, diabetes, thyroid function); (6) widelydistribute 62Zn/62Cu generators to meet clinical trial and patient care demands; and (7) harmonizeimplementation of this method across diverse imaging environments via standardized quantitative data andimage analysis tools. The key innovation of this research will be advancement of a quantitative whole-bodyperfusion imaging method from the research laboratory into a complete set of validated tools that enable robustand standardized application in clinical trials and patient care throughout the imaging community.
StatusActive
Effective start/end date7/1/166/30/21

Funding

  • National Institutes of Health: $591,408.00

Fingerprint

Perfusion Imaging
Perfusion
Clinical Trials
Neoplasms
Patient Care
Software
Research
Cardiovascular Abnormalities
Thiosemicarbazones
Phenotype
Precision Medicine
Peripheral Vascular Diseases
Body Image
Clinical Medicine
Therapeutic Uses
Tumor Biomarkers
Pharmaceutical Preparations
Comorbidity
Copper
Thyroid Gland